Stress permeates life for all of us, but for the millions of people living with epilepsy, it may be a significant precipitant for their seizures. Between 25 and 50 percent of surveyed people with epilepsy report stress as a trigger, making it the most commonly reported precipitant (1-4). If stress is indeed a trigger, then logically, reducing stress should decrease seizure frequency. Imagine the impact prescribing relaxation in lieu of a multitude of antiepileptic drugs could have on patients. If it were only that simple. Stress is a multiheaded monster that draws contributions from external events in our environment that cause stress, an individual's subjective appraisal of events and ability to react to them, and finally neurophysiologic responses triggered by these events (4). While a number of studies have investigated the causal relationships between stress and epilepsy, the results are inconsistent and suffer from the inability to accurately characterize stress, separate it from other comorbid psychological disorders (i.e., anxiety, depression), and delineate the contribution of stress versus other downstream impacts, such as sleep deprivation. As a result, it is difficult to tease out how stress (both acute and chronic)
impacts seizure frequency and the mechanism by which we treat stress to reduce seizures.
Haut and colleagues sought to demonstrate that progressive muscle relaxation (PMR), a method by which each muscle set is tensed and relaxed, could effectively reduce seizures through stress reduction. They compared this intervention to a control treatment of focused attention (FA) in a double-blind fashion. The treatment approach was novel and the design unique, yet the authors failed to show a difference between the two methods, as both were associated with reduced seizure frequency (25% FA vs 29% PMR) and stress over the 3-month study compared with baseline. The authors concluded that the response was not only clinically meaningful but was the result of the interventions, which raises a variety of clinical and design questions that may shape future behavioral research of similar aim.
Which patients should be included in epilepsy studies of behavioral interventions? In this cohort, patients were 18 years or older and had medically resistant focal epilepsy. While all were aware of precipitating factors for their seizures, 86% regarded stress as a trigger. While it is reasonable to assume that all patients experience stress and may benefit from the intervention, a more robust response might be seen when the therapy is directed at those impacted most by stress. In addition, the authors excluded patients with a recent suicide attempt or more severe anxiety and depression-yet another subgroup that might benefit more from behavioral interven- OBJECTIVE: To evaluate the effect of a stress-reduction intervention in participants with medication-resistant epilepsy. METHODS: Adults with medication-resistant focal epilepsy (n = 66) were recruited from 3 centers and randomized to 1 of 2 interventions: (1) progressive muscle relaxation (PMR) with diaphragmatic breathing, or (2) control focused-attention activity with extremity movements. Following an 8-week baseline period, participants began 12 weeks of doubleblind treatment. Daily self-reported mood and stress ratings plus seizure counts were completed by participants using an electronic diary, and no medication adjustments were permitted. The primary outcome was percent reduction in seizure frequency per 28 days comparing baseline and treatment; secondary outcomes included stress reduction and stress-seizure interaction. RESULTS: In the 66 participants in the intention-to-treat analysis, seizure frequency was reduced from baseline in both treatment groups (PMR: 29%, p < 0.05; focused attention: 25%, p < 0.05). PMR and focused attention did not differ in seizure reduction (p = 0.38), although PMR was associated with stress reduction relative to focused attention (p < 0.05). Daily stress was not a predictor of seizures. CONCLUSIONS: Both PMR and the focusedattention groups showed reduced seizure frequency compared to baseline in participants with medication-resistant focal seizures, although the 2 treatments did not differ. PMR was more effective than focused attention in reducing self-reported stress.
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tions. Until we better understand the relationships between stress and seizures, it seems reasonable to focus on cohorts that self-identify stress as a primary trigger for best results.
How do we develop adequate controls for such studies? The assumption at the outset was that FA would be ineffective at improving stress, but that assumes that stress is the driving component of the seizure trigger. In fact, as the authors note, FA and the detailed psychological assessment the participants received, may have improved mindfulness, a technique previously demonstrated to reduce seizures (5). In addition, simply being in the study likely had some impact. The Hawthorne effect-spontaneous improvement seen in groups when they are observed regardless of intervention-contributes to placebo response and may have been in play (6) . In addition, stress may have been reduced by providing uniformity and stability to those in the study or by simply lending some hope that a new intervention would help reduce seizures. Both groups demonstrated reduced stress during the baseline phase, before any treatment, suggesting that simply being involved in a study was helpful. To separate the contribution of these factors, a longer study using a delayed start to treatment may be necessary.
One has to further question how other components of placebo response contributed to the results. The authors noted that seizure reduction rates of 25 percent to 29 percent on therapy were superior to placebo rates in both drug and nonpharmacologic intervention trials. However, with recent pharmaceutical trials demonstrating response rates in nearly 20% of the placebo group, is this difference statistically significant (7)? The placebo response is a complicated construct that could be affected by a variety of additional variables, none potentially more important for this study than regression to the mean. The participants were not consecutively recruited but instead opted to participate; thus, they may have been in an upswing of their epilepsy when they decided to enroll, only to regress to their baseline over time. Regression to the mean tends to resolve over 3 to 6 months, and this study may have been too short to exclude that contribution (6) . One of the unique characteristics of the study design was double blinding-meaning the investigators were not aware which intervention the patients were exposed to, and the patients were unaware which intervention was hypothesized to be effective. However, several studies have demonstrated that expectation, knowledge, and belief about a treatment can impact response, so simply knowing you are getting an intervention will have some impact (8) . Again, this is difficult to separate when the control intervention likely has some treatment effect as well.
Finally, was the duration of the study adequate to produce a response? The seizure reduction of the PMR group reached a peak in month two (46%) but then declined, while the FA group showed steady improvement throughout, reaching 34% by study end. Without a longer baseline to assess the natural fluctuations of disease, it is difficult at best to separate natural fluctuation from true treatment response. Given that stress is not just an acute reaction but also a chronic symptom, 3 months of treatment may be inadequate to modulate changes both psychologically and physiologically. Seizure reduction seen with chronic vagal nerve stimulation and cognitive improvements after epilepsy surgery can take years to manifest after treatment; thus, treatment response to behavioral interventions may take time to manifest (8, 9) .
In the end, behavioral interventions may be beneficial for reducing seizure frequency, though the magnitude of response pales in comparison to other pharmacologic and nonpharmaceutical therapies. Behavioral interventions may demonstrate improved response with longer duration of therapy, targeted treatment to specific populations and symptoms, and better understanding of the true relationships of stress and other triggers. This approach to treatment is without much downside in regards to adverse effect and is mostly limited by cost of instruction and the patient's willingness to practice the treatment. While substantially more study will be needed to clarify the value, behavioral interventions likely have a place in treatment plans for some patients. This study underscores the complexity of stress and epilepsy and the inherent difficulties in researching behavioral interventions.
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